Compare SSP & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSP | IKT |
|---|---|---|
| Founded | 1878 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.6M | 220.5M |
| IPO Year | 1998 | 2020 |
| Metric | SSP | IKT |
|---|---|---|
| Price | $2.75 | $1.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $6.95 | $5.00 |
| AVG Volume (30 Days) | ★ 574.7K | 541.3K |
| Earning Date | 05-07-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.76 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,150,585,000.00 | N/A |
| Revenue This Year | $8.34 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.04 | $1.33 |
| 52 Week High | $5.39 | $2.26 |
| Indicator | SSP | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 29.81 | 58.93 |
| Support Level | $2.73 | $1.63 |
| Resistance Level | $3.01 | $1.91 |
| Average True Range (ATR) | 0.21 | 0.07 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 21.37 | 95.12 |
The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.